This Day On The Street
Continue to site
ADVERTISEMENT
This account is pending registration confirmation. Please click on the link within the confirmation email previously sent you to complete registration.
Need a new registration confirmation email? Click here

Dan's Most Recent Article

Buying Bluebird's Blockbuster Potential at a Discount

07/17/14 - 10:33 AM EDT

It's not often an investor gets the opportunity to buy a biotech stock with two blockbuster indications in the pipeline and major catalysts only months away at such a discount.

read more >

Other Articles by Dan

Free Reports

Why I'm More Confident in Sarepta Than Ever Before Why I'm More Confident in Sarepta Than Ever Before

11/04/13 - 10:06 AM EST

Biotech trader Dan Rosenblum believes the recent selloff in Sarepta is a tremendous buying opportunity.

read more >
Sarepta: Staying Long and Strong Sarepta: Staying Long and Strong

04/25/13 - 09:25 AM EDT

Contributor Dan Rosenblum believes Sarepta's upside potential far outweighs the risk in the stock.

read more >
Sarepta Is Undervalued Even Without Eteplirsen Accelerated Approval Sarepta Is Undervalued Even Without Eteplirsen Accelerated Approval

03/05/13 - 10:39 AM EST

The exon-skipping drug technology is worth a lot more than just eteplirsen alone.

read more >
Insider Buying at Auxilium, Aveo Hints At Big Moves in 2013 Insider Buying at Auxilium, Aveo Hints At Big Moves in 2013

12/20/12 - 07:30 AM EST

Insiders at Auxilium and Aveo appear to be betting on turnarounds for both stocks in the next year.

read more >
Still Bullish on BioMarin, Lexicon Pharma Still Bullish on BioMarin, Lexicon Pharma

11/07/12 - 11:28 AM EST

TheStreet contributor Dan Rosenblum explains why he still likes BioMarin and Lexicon Pharma.

read more >
Sunshine Heart: A Promising Treatment for Heart Failure Patients Sunshine Heart: A Promising Treatment for Heart Failure Patients

11/05/12 - 08:00 AM EST

Sunshine's C-Pulse is a heart-assist device for patients who fall between the cracks of current therapy.

read more >
Lexicon Pharma: Blockbuster Potential From A Diabetes Drug Lexicon Pharma: Blockbuster Potential From A Diabetes Drug

10/16/12 - 06:10 AM EDT

Lexicons mid-stage diabetes drug blocks the reabsorption of blood sugar.

read more >
Biomarin: Four Clinical Trial Events to Watch Before Year End Biomarin: Four Clinical Trial Events to Watch Before Year End

09/25/12 - 07:03 AM EDT

TheStreet contributor Dan Rosenblum explains why Biomarin is a very busy biotech.

read more >
Nanosphere: A Low-Risk, High-Growth Diagnostic Stock Nanosphere: A Low-Risk, High-Growth Diagnostic Stock

09/18/12 - 07:13 AM EDT

A hospital-based sepsis test is the launching pad for Nanosphere.

read more >
Page 1 of 2
< Previous
Top Rated Stocks Top Rated Funds Top Rated ETFs